Netherlands · Funded startup

Who invested in Micreos

2 rounds we have observed, with the 0 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 15 Nov 2026

$34Mraised across 2 rounds since 2012, from 2 sources

Latest round
Round, $34MApr 2019
Investors
0
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20122013201420152016201720182019
?Round$34MRound
First round
Round
May 2012
Biggest round
$34M
Round · Apr 2019
Between rounds
6.8 years
from the last two

The rounds

  1. Apr 2019
    Round$34M

    No investor was named in the report.

    Reported by Biotech-365

  2. May 2012
    RoundAmount undisclosed

    No investor was named in the report.

    Reported by finsmes.com

Founders and team

From Micreos's own website: 8 on the team.

  • Matt ReganChief Executive Officer, Director
  • Martin VlasatyChief Financial Officer
  • Matthew Dunnechief development & science officer
  • Dr. Bob de Rooijhead of preclinical
  • Dr. Markus Huemerhead of Protein Engineering
  • Fabienne ArnPrincipal Scientist
  • Hana Pituerovalab manager
  • Patrick Vinkboard member

Quick answers about Micreos

How much has Micreos raised?

Micreos has raised $34M across 2 rounds since 2012. One round did not disclose an amount, so the total is a floor.

When did Micreos last raise?

Micreos's most recent round was an Undisclosed round of $34M in Apr 2019.

What was Micreos's biggest round?

Its most recent round, $34M in Apr 2019, is also its largest on record.

What stage is Micreos at?

Micreos's latest named round is an Undisclosed round, in Apr 2019.

Where is Micreos based?

Micreos is based in the Netherlands.

Companies like Micreos

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.